Enzymatics Inc. has acquired ArcherDx Inc. in a deal valued at up to $50 million.

ArcherDx, headquartered in Denver, Colo., develops software used to analyze cancer treatments.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.